MASIMO CORP (MASI)
Health Care / Health Care Equipment
S&P MidCap 400$177.98
Middle of the pack. No strong signal either way.
Consider Buy
Score based on 4 of 5 models — moderate confidence
Is MASIMO CORP a Good Investment in 2026?
MASIMO CORP (MASI) scores 6.9 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates MASIMO CORP as Strong (7/9). The Graham model is the least favorable, rating it Neutral. MASIMO CORP currently trades above its estimated fair value of $93, suggesting limited upside at current prices. MASIMO CORP ranks #109 out of 1127 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Estimated Fair Value
Trading above estimated fair value — the market may be pricing in future growth.
Model-based estimate, not a price target.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Strong
7/9
Buffett
Neutral
Business quality & competitive moat
Graham
Neutral
Price vs intrinsic value
Lynch
Attractive
Growth rate vs price (PEG)
Greenblatt
Strong
Top 10% (rank 8%)
Frequently Asked Questions
Is MASIMO CORP (MASI) a good investment?
What is MASIMO CORP's Piotroski F-Score?
Is MASI overvalued or undervalued?
How does MASI compare to other Health Care stocks?
What do investment models say about MASI?
Similar Stocks
Compare MASI with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer